Kintor Pharmaceutical Limited
KNTPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$119.15M
Close$
$-0.04
115.9% downside
Current Fair Value
115.9% downsideOvervalued by 115.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $119.15 Million |
|---|---|
| Enterprise Value | $220.93 Million |
| Earnings per Share | $-0.43 |
| Beta | -0.57 |
| Outstanding Shares | 493,379,000 |
Return
| Return on Equity | -255.15% |
|---|---|
| Return on Assets | -87.38% |
| Return on Invested Capital | -207.88% |
Valuation & Multiples
| P/E Ratio | -3.12 |
|---|---|
| PEG | -0.56 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.73 |
| Enterprise Value to EBIT | -0.78 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.6 |
| Debt to Equity | 1.22 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Kintor Pharmaceutical Limited
122 employees
CEO: Youzhi Tong
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concent...